Table 1 Baseline features of non-severe aplastic anemia (NSAA) patients. Values are given as median (range) unless otherwise specified.

From: Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study

Baseline features

Untreated

CyA

ATG + CyA

CyA + EPAG

EPAG

Other

All patients

N

76

84

44

20

10

25

259

Male/Female

28/48

36/48

22/22

11/9

5/5

12/13

114/145

Age, years*

36 (7–85)

57 (14–91)

43 (16–71)

68 (21–83)

70 (29–80)

36 (6–86)

50 (6–91)

Hb, g/dL

11.7 (7.7–15.1)

9.8 (4.5–14.7)

9.4 (7–13.8)

8.5 (5.2–14.3)

8.6 (6.3–11.9)

9.2 (5.6–11.8)

9.5 (4.5–15.1)

PLT ×10^9/L**

86 (31–216)

31 (4–182)

26 (7–102)

24 (5–53)

24 (3–43)

30 (8–210)

34 (4–216)

ANC ×10^9 L

1.6 (0.4–7.2)

1.16 (0.03–8.8)

1.09 (0.6–2.7)

1.3 (0.5–4.9)

1.21 (0.26–2.5)

1.15 (0.37–6.54)

1 (0.03–8.8)

Ret ×10^9/L

60 (21–134)

59 (4–57)

60 (20–80)

50 (20–110)

50 (10–140)

40 (20–63)

52 (4–140)

LDH U/L

206 (135–1947)

221 (94–1036)

218 (159–300)

220 (140–347)

192 (106–799)

211 (148–357)

240 (94–1947)

endogenous EPO U/L

88 (12–1438)

524 (3.9–5032)

534 (69–1865)

151 (85–1248)

240 (56–728)

383 (94–1053)

380 (3.9–5032)

PNH clone, N

22/59

36/77

26/35

9/20

5/10

11/21

109/222

Size, %

7.2 (0.05–99.4)

2.5 (0.0–93.3)

1.4 (0–13)

0.9 (0.01–16.3)

0 (0–2)

4.5 (0–99)

1.5 (0.1–99)

RBC transfusion, N**

5/39

59/84

15/40

12/20

10/10

15/25

116/218

PLT transfusion, N**

1/39

42/84

10/40

9/20

8/10

11/25

81/218

Trephine cellularity, %

15 (2–40)

10 (3–50)

10 (1–30)

10 (3–30)

20 (3–40)

10 (3–60)

15 (5–60)

MF-0, N

21/31

48/71

10/19

13/16

5/9

7/13

104/159

MF-1, N

10/31

21/71

8/19

3/16

4/9

6/13

52/159

MF-2, N

0/31

2/71

1/19

0/16

0/9

0/13

3/159

Lymphoid infiltrate, N

11/31

25/71

5/19

9/16

7/9

6/14

63/160

T/B/mixed, N

10/0/1

9/1/15

4/1/0

7/0/2

2/1/4

3/0/3

35/3/25

Abnormal karyotype, N

3/66

2/83

5/40

2/19

0/10

2/23

14/241

Abnormal NGS, N

6/36

5/47

0/8

4/18

2/7

5/16

22/132

  1. Endogenous erythropoietin was not available in 12 cases, karyotype in 18, FC in 99, and NGS in 127 patients. For 41 patients, mainly untreated and mildly cytopenic, transfusion records were not available from clinical charts.
  2. CyA cyclosporine, ATG anti-thymocyte globulin, EPAG eltrombopag, Hb hemoglobin, PLT platelets, ANC absolute neutrophil counts, Ret reticulocytes, LDH lactate dehydrogenase, EPO erythropoietin, PNH paroxysmal nocturnal hemoglobinuria, RBC red blood cell, NGS next-generation sequencing.
  3. *p < 0.01; **p < 0.001.
Back to article page